Toward future therapies in progressive supranuclear palsy
Identifieur interne : 004D81 ( Main/Merge ); précédent : 004D80; suivant : 004D82Toward future therapies in progressive supranuclear palsy
Auteurs : David J. Burn [Royaume-Uni] ; Naomi M. Warren [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
English descriptors
- KwdEn :
- Adrenergic Agents (therapeutic use), Anti-Dyskinesia Agents (therapeutic use), Cholinergic Agents (therapeutic use), Dopamine Agents (therapeutic use), Humans, Neurotransmitter Agents (therapeutic use), Palliative Care, Steele–Richardson–Olszewski syndrome, Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (therapy), progressive supranuclear palsy, treatment, trophic factors.
- MESH :
- chemical , therapeutic use : Adrenergic Agents, Anti-Dyskinesia Agents, Cholinergic Agents, Dopamine Agents, Neurotransmitter Agents.
- drug therapy : Supranuclear Palsy, Progressive.
- therapy : Supranuclear Palsy, Progressive.
- Humans, Palliative Care.
Abstract
There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20546
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E31
- to stream Istex, to step Curation: 001E31
- to stream Istex, to step Checkpoint: 002104
- to stream PubMed, to step Corpus: 002F30
- to stream PubMed, to step Curation: 002F30
- to stream PubMed, to step Checkpoint: 002F30
- to stream Ncbi, to step Merge: 001382
- to stream Ncbi, to step Curation: 001382
- to stream Ncbi, to step Checkpoint: 001382
Links to Exploration step
ISTEX:F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward future therapies in progressive supranuclear palsy</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20546</idno><idno type="url">https://api.istex.fr/document/F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E31</idno><idno type="wicri:Area/Istex/Curation">001E31</idno><idno type="wicri:Area/Istex/Checkpoint">002104</idno><idno type="wicri:doubleKey">0885-3185:2005:Burn D:toward:future:therapies</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16092097</idno><idno type="wicri:Area/PubMed/Corpus">002F30</idno><idno type="wicri:Area/PubMed/Curation">002F30</idno><idno type="wicri:Area/PubMed/Checkpoint">002F30</idno><idno type="wicri:Area/Ncbi/Merge">001382</idno><idno type="wicri:Area/Ncbi/Curation">001382</idno><idno type="wicri:Area/Ncbi/Checkpoint">001382</idno><idno type="wicri:doubleKey">0885-3185:2005:Burn D:toward:future:therapies</idno><idno type="wicri:Area/Main/Merge">004D81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Toward future therapies in progressive supranuclear palsy</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S92">S92</biblScope><biblScope unit="page" to="S98">S98</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8</idno><idno type="DOI">10.1002/mds.20546</idno><idno type="ArticleID">MDS20546</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents (therapeutic use)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Cholinergic Agents (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Humans</term><term>Neurotransmitter Agents (therapeutic use)</term><term>Palliative Care</term><term>Steele–Richardson–Olszewski syndrome</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (therapy)</term><term>progressive supranuclear palsy</term><term>treatment</term><term>trophic factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Agents</term><term>Anti-Dyskinesia Agents</term><term>Cholinergic Agents</term><term>Dopamine Agents</term><term>Neurotransmitter Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Palliative Care</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies. © 2005 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20546"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward future therapies in progressive supranuclear palsy</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20546</idno><idno type="url">https://api.istex.fr/document/F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E31</idno><idno type="wicri:Area/Istex/Curation">001E31</idno><idno type="wicri:Area/Istex/Checkpoint">002104</idno><idno type="wicri:doubleKey">0885-3185:2005:Burn D:toward:future:therapies</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Toward future therapies in progressive supranuclear palsy</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S92">S92</biblScope><biblScope unit="page" to="S98">S98</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8</idno><idno type="DOI">10.1002/mds.20546</idno><idno type="ArticleID">MDS20546</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Steele–Richardson–Olszewski syndrome</term><term>progressive supranuclear palsy</term><term>treatment</term><term>trophic factors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies. © 2005 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward future therapies in progressive supranuclear palsy.</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M" last="Warren">Naomi M. Warren</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20546</idno><idno type="RBID">pubmed:16092097</idno><idno type="pmid">16092097</idno><idno type="wicri:Area/PubMed/Corpus">002F30</idno><idno type="wicri:Area/PubMed/Curation">002F30</idno><idno type="wicri:Area/PubMed/Checkpoint">002F30</idno><idno type="wicri:Area/Ncbi/Merge">001382</idno><idno type="wicri:Area/Ncbi/Curation">001382</idno><idno type="wicri:Area/Ncbi/Checkpoint">001382</idno><idno type="wicri:doubleKey">0885-3185:2005:Burn D:toward:future:therapies</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toward future therapies in progressive supranuclear palsy.</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M" last="Warren">Naomi M. Warren</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents (therapeutic use)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Cholinergic Agents (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Humans</term><term>Neurotransmitter Agents (therapeutic use)</term><term>Palliative Care</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Agents</term><term>Anti-Dyskinesia Agents</term><term>Cholinergic Agents</term><term>Dopamine Agents</term><term>Neurotransmitter Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Palliative Care</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004D81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:F7957A9A6A75DE74DDE1FB7BEC862510BE576CD8
|texte= Toward future therapies in progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.23. |  |